(Q48485039)

11 February 2018

title

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). (English)

1 reference

11 February 2018

chronic obstructive pulmonary disease

main subject

patient

0 references

1 reference

1 reference

ChEBI release 2020-05-28

Edward M Kerwin

1

1 reference

11 February 2018

Anthony D D'Urzo

2

1 reference

11 February 2018

Arthur F Gelb

3

1 reference

11 February 2018

Hassan Lakkis

4

1 reference

11 February 2018

Esther Garcia Gil

5

1 reference

11 February 2018

Cynthia F Caracta

6

1 reference

11 February 2018

ACCORD I study investigators

7

1 reference

11 February 2018

language of work or name

English

0 references

publication date

9 February 2012

1 reference

11 February 2018

COPD: Journal of Chronic Obstructive Pulmonary Disease

published in

1 reference

11 February 2018

volume

9

1 reference

11 February 2018

issue

2

1 reference

11 February 2018

page(s)

90-101

1 reference

11 February 2018

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

cites work

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Global burden of COPD: risk factors, prevalence, and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

The impact of COPD on lung health worldwide: epidemiology and incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Standardisation of spirometry

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Development of a sleep diary for chronic pain patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

The MCID of the transition dyspnea index is a total score of one unit

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Minimal clinically important differences in COPD lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Withdrawal from treatment as an outcome in the ISOLDE study of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

A one-year trial of tiotropium Respimat plus usual therapy in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

Symptom variability in patients with severe COPD: a pan-European cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2012.661492

10.3109/15412555.2012.661492

21 January 2018

Identifiers

DOI

1 reference

11 February 2018

release_35b66mh2dbb7rby5vdd7gwxxrq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/35b66mh2dbb7rby5vdd7gwxxrq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

11 February 2018